Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
pancreatic neoplasms/l tyrosine
Le lien est enregistré dans le presse-papiers
9 résultats
AKT tyrosine 176 phosphorylation cancer biomarker
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF INVENTION
This invention relates to methods and compositions for the diagnosis, classification, and treatment of cancer. More specifically, this invention is a method of identifying cancer using novel protein phosphorylation status.
BACKGROUND OF THE INVENTION
The intracellular tyrosine
DNA damaging agents in combination with tyrosine kinase inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the field of biochemical pathways. More particularly, it concerns the pathways connecting DNA damage and phosphorylation by tyrosine kinaseses.
2. Description of the Related Art
Current treatment methods
Antibodies
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 11, 2016, is named OTJ_009US_Sequence.txt and is 27,712 bytes in
Annexin A2 as immunological target
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
TECHNICAL FIELD OF THE INVENTION
This invention is related to the area of tumor immunology. In particular, it relates to highly immunogenic proteins found on tumor cells.
BACKGROUND OF THE INVENTION
Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignant disease with a median survival of
6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to 6,7-dialkoxy quinazoline derivatives, or pharmaceutically acceptable salts thereof, which possess anti-cancer activity and hence useful in methods of treatment in humans. The invention also relates to processes for the manufacture of the said
Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD
This disclosure concerns inhibitors of the T-cell specific alternative p38 activation pathway and their use for the treatment of p38-associated diseases, such as autoimmune and inflammatory disorders, including inflammatory cancers. In particular, this disclosure concerns Gadd45.alpha.
6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to 6,7-dialkoxy quinazoline derivatives, or pharmaceutically acceptable salts thereof, which possess anti-cancer activity and hence useful in methods of treatment in humans. The invention also relates to processes for the manufacture of the said
Pyrimido compounds having antiproliferative activity
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention is directed to novel pyrimido compounds that inhibit the Src family of non-receptor tyrosine kinases (SFKs). These compounds and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer,
Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The present invention relates to a method for treating patients afflicted with cancer, wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
